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The current study analyzed reverse phase protein arrays (RPPA) as a means to experimentally
validate biomarkers in blood samples. One microliter samples of sera (n = 71), and plasma
(n = 78) were serially diluted and printed on NC-coated slides. CA19-9 levels from RPPA results
were compared with identical patient samples as measured by ELISA. There was a strong corre-
lation between RPPA and ELISA (r = 0.87) as determined by scatter plots. Sample reproducibility
of CA19-9 levels was excellent (interslide correlation r = 0.88; intraslide correlation r = 0.83). The
ability of RPPA to accurately distinguish CA19-9 levels between cancer and noncancer samples
were determined using receiver operating characteristic curves and compared with ELISA. The
AUC for RPPA and ELISA was comparable (0.87 and 0.86, respectively). When the mean CA19-9
levels of normal samples was used as a cutoff for RPPA and compared with the standard clinical
ELISA cutoff, comparable specificities (71% for both) were observed. Notably, RPPA samples
normalized to albumin showed increased sensitivity compared to ELISA (90% vs. 75%). As RPPA
is a high-throughput method that shows results comparable to that of ELISA, we propose that
RPPA is a viable technique for rapid experimental screening and validation of candidate bio-
markers in blood samples.
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1 Introduction
Despite the dire need for, and great interest in, utilizing
blood biomarkers as an early, reliable, and noninvasive
means of detecting diseases such as cancer, the number of
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clinically relevant markers remains disappointingly low [1–
4]. One case in point is pancreatic cancer. This cancer is
relatively uncommon, being the 10th most frequent in inci-
dence among males in the USA. Nevertheless, it ranks as the
4th highest in mortality in both men and women [5]. Effec-
tive treatments for pancreatic cancer are not widely available
due to the typically late stage detection of the disease, and
lack of reliable, cost-effective early detection methods. In
clinical practice, the biomarker CA19-9 is typically used.
While this marker is not useful for early detection, it is useful
for monitoring the effects of cancer therapy and detecting
recurrence [6, 7]. Several studies have defined a large group
of candidate pancreatic cancer biomarkers based on gene
profiling [8–10] and proteomics [11, 12]. A few of these can-
didates have been further validated using patient samples
[13]. However, many other potential biomarkers remain
unexamined due to the cost and difficulty of the validation
studies. A recent review article summarizes the development
of biomarkers in pancreatic cancer [3].
Standard approaches to biomarker validation involve
ELISA or Luminex assays. The standard ELISA or Luminex
assay utilizes two antibodies and one concentration of sam-
ple. In the case of pancreatic cancer, CA19-9 levels are routi-
nely determined in clinical laboratories by an ELISA, which
typically has a dynamic range of about log10(1.4) for linear
range detection of the signal. Reliance on two antibodies,
whether in ELISA or Luminex assays, places constraints in
screening and validation assays, including identification of
two specific antibodies that do not interfere with each other,
and in the case of multiplexing, limits the number of mark-
ers assayable in a single sample due to increased likelihood
of crossreactivity. Conversely, reliance on one concentration
of sample could result in extrapolating rather than inter-
polating protein levels, resulting in inaccurate quantification
of sample. Therefore, the current standard methodologies
for ELISA and Luminex limit their ability to perform accu-
rate, high-throughput screening, and validation for bio-
markers.
RP protein array (RPPA) is becoming widely used in
quantifiable, moderately high throughput protein analyses.
Techniques enabling quantification in RPPA include serial
dilution of samples and use of a “supercurve” [14] to inter-
polate all samples contained on a slide. Scores of slides can
be printed from a master plate, enabling analyses of dozens
of proteins on hundreds to thousands of samples. In cancer
research, RPPA has been successfully used to detect differ-
ences in total protein levels or PTMs in cancer cell lysates as
diverse as blood (acute myeloid leukemia) [15], prostate [16],
and rhabdomyosarcoma [17]. While detection of potential
cancer biomarkers in serum has been reported for SELDI-
TOF [7, 18], RPPA application has not yet been reported for
serum markers in cancer.
To validate the use of RPPA on serum or plasma, we
assayed for CA19-9 levels in samples of normal individuals
or those diagnosed with chronic pancreatitis or pancreatic
adenocarcinoma. We compared CA19-9 levels measured by
ELISA with those obtained using RPPA and demonstrated
that RPPA is comparable to ELISA for determining CA19-9
levels in serum and plasma. Further, we observed that RPPA
has increased sensitivity compared to ELISA for CA19-9
levels in cancer versus noncancer individuals when samples
were adjusted for loading. As RPPA allows for serial dilution
of hundreds of samples, printing of multiple slides, and has
demonstrated results comparable to that of ELISA, RPPA is a
viable technique for rapid screening and validation of candi-
date biomarkers in serum.
2 Materials and methods
2.1 Patient samples
Plasma samples were collected at The University of Texas
M. D. Anderson Cancer Center in collaboration with TexGen
Research Project, which organizes sample collection and
storage for several institutions in the Houston Medical Cen-
ter. TexGen provided plasma samples of pancreatic adeno-
carcinoma patients as well as age-matched controls. In order
to test a broader sample collection including chronic pan-
creatitis and other serum samples, we also acquired chronic
pancreatitis serum from the University of Pittsburgh and
normal and cancer serum from the University of Michigan.
Samples were obtained during routine diagnostic procedures
following written patient consent. IRB approval was also
obtained from the three participating institutions. For the
current study, 71 serum and 78 plasma samples were avail-
able from patients with pancreatic adenocarcinoma or
chronic pancreatitis and healthy controls (for details, see
Table 1).






Normal control Plasma TexGen 37
Pancreatic cancer Plasma TexGen 41
Normal control Serum University of Michigan 11
Chronic pancreatitis Serum University of Pittsburgh 30
Pancreatic cancer Serum University of Michigan 30
Total 149
2.2 Reagents and cell lines
Anti-CA19-9, albumin, and IgM antibodies were purchased
from Fitzgerald Industries International (Concord, MA). Cell
lines used as controls were human pancreatic cancer cell
lines BxPC3, MPanc96, MIA PaCa-2, and PANC-1. Also used
was the nontransformed cell line HPDE (human pancreatic
duct epithelium) and the primary cancer cell line MOH.
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BxPC3, MIA PaCa-2, and PANC-1 were purchased from the
American Type Culture Collection (Manassas, VA); HPDE
was kindly provided by Dr. Ming-Sound Tsao (University of
Toronto, Ontario, Canada) [19]. MPanc96 was provided by Dr.
Timothy J. Eberlein (St. Louis, MO) [20] and MOH was pro-
vided by Dr. Mohammed Hussain (Wayne State University,
Detroit, MI). Cells were grown in serum-free medium for
24 h (RPMI for BxPC3 and MOH; DMEM for MIA PaCa-2,
PANC-1, and MPanc96; Keratinocyte medium for HPDE).
All media contained 1% antibiotics and antimycotic.
2.3 RPPA sample preparation
Cells lines at log phase growth were rinsed twice with ice
cold PBS without divalent cations, and were lysed upon
addition and incubation for 20 min of ice cold lysis buffer
(1% Triton X-100, 50 mM HEPES (pH 7.4), 150 mM NaCl,
1.5 mM MgCl2, 1 mM EGTA, 100 mM NaF, 10 mM NaPPi,
10% glycerol, supplemented with Complete Protease Inhibi-
tor tablets (Boehringer/Roche, Mannheim, Germany) and
1 mM Na3VO4) with occasional rocking. Cells were scraped;
lysates were centrifuged for 10 min at 47C at 13 000 rpm in a
microcentrifuge. The supernatant was collected; protein
concentration was determined by BCA (Pierce Biotechnol-
ogy, Rockford, IL). All samples were denatured by adding 1
part 46SDS sample buffer (35% Glycerol, 8% SDS, 250 mM
Tris (pH 6.8), 10% 2-mercaptoethanol) to 3 parts lysate and
boiling for 5 min. Protein concentration of cell line samples
were adjusted to 1 mg/mL prior to serial dilutions for RPPA
using dilution buffer (three parts lysis buffer:one part
46SDS buffer).
Serum and plasma samples were also denatured as
described above. Prior to serial dilutions, samples were initi-
ally diluted 1:10 using dilution buffer. This initial concentra-
tion was determined from previous studies as the optimal
starting concentration (data not shown). Processed samples
were serially diluted two-fold (final volume 10 mL) with dilu-
tion buffer in 96-well plates. Equal volumes of 80% glycer-
ol 1 26PBS buffer were added to each well and transferred
into 384-well master plates for printing. Samples were sealed
and stored at 2807C until use. One hundred ninety-two
samples comprising 37 normal plasma, 41 cancer plasma, 11
normal serum, 30 chronic pancreatitis serum, and 30 cancer
serum samples; 30 duplicates (6 samples from each group); 6
control cell lines, and 7 negative spots (lysis buffer) were
processed.
2.4 RPPA sample printing
Array set up was a 466 grid using a 200 mm solid pin 48-pin
head in a GeneTAC G3 arrayer (Genomic Solutions, Ann
Arbor, MI), with each sample represented as a series of six
dilutions in one row within the grid. The samples were
printed 4 touches/spot with spots 700 mm apart on NC-
coated FAST slides (Whatman, Florham Park NJ). Slides
were stored at 2207C in desiccant until use.
2.5 RPPA slide staining
Protein detection was accomplished by tyramide-based sig-
nal amplification and a colorimetric substrate (Catalyzed
Signal Amplification System; CSA) (Dako, Carpinteria, CA)
using a procedure similar to that of Paweletz et al. [21].
Staining was performed on the i6000 autostainer from Bio-
Genex (San Ramon, CA). Specifically, slides were precleared
with Re-Blot Plus Mild Antibody Stripping Solution (Che-
micon International, Temecula, CA) for 5 min, and washed
with RPPA TBS-T (300 mM NaCl, 50 mM Tris (pH 7.6),
0.1% Tween-20). Slides were then blocked with 0.2% I-Block
(Applied Biosystems, Foster City, CA) in PBS containing
0.1% Tween-20 for 30 min. Following a TBS-T rinse, slides
were further blocked for peroxidase, avidin, biotin, and pro-
teins (5 min per reagent followed by washes with RPPA TBS-
T), then incubated for 20 min with primary antibody. Con-
centrations used for primary antibodies were as follows:
CA19-9 (1:2000), albumin (1:1000), and IgM (1:500). Follow-
ing washes, a 1:15 000 dilution of the appropriate biotiny-
lated secondary antibody (Vector Laboratories, Burlingame,
CA), was added, and incubated for 20 min. Antibodies were
diluted in Background Reducing Antibody Diluent (Dako).
The slides were washed with RPPA TBS-T, and the three
amplification reagents from the Dako CSA kit (Streptavidin–
Biotin Complex, Amplification Reagent, Streptavidin-HRP)
were added for 15 min each, followed by RPPA TBS-T
washes. For signal detection, diaminobenzidine was added to
the slide and incubated for 3 min; the reaction was stopped
by washing the slide in ddiH2O. The slides were then air-
dried for scanning and quantification.
2.6 RPPA sample quantification
Slides were scanned on an HP Scanjet 8200 flatbed scanner
at 600 dpi in grayscale, and saved as a 16-bit tiff file. Spot
intensities, determined as mean net values in which local
background intensity was subtracted, were determined by
reading tiff images on MicroVigene software (Vigene Tech,
North Billerica, MA). Protein levels of samples relative to
each other on a given slide were interpolated from the
“supercurve” library constructed for RPPA that was written
in the statistical language R [14]. A full technical description
of this work is given in the referenced paper. Briefly, the
supercurve quantification relies on utilizing all spot inten-
sities of all samples on the slide, and is designed on the pre-
mise that each antibody has binding properties that are
characteristic and unique to itself. An antibody response
curve for each slide is fit in an iterative fashion. First, a re-
sponse curve is estimated for the slide, then concentrations
are estimated for each sample, and an improved response
curve is fit for the slide based on these sample concentra-
tions; this is continually iterated between estimating the
slide response curve and estimating sample concentrations
until convergence is obtained. To fit this response curve, the
known dilutions within each sample were used and defined
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constraints were placed on the form of the sample response
curve for the slide. For this data, we found a logistic response
curve was a good fit for the antibodies used. This fitted
logistic response curve is what we call “supercurve”. Fur-
thermore, robust statistical methods were used in fitting the
response curve to account for possible outliers within a dilu-
tion series. Goodness of fit of supercurve for each slide was
determined by (i) calculating a mean R2 of the linear portion
of the curve (“trimmed mean R2”) for how well each intensity
fit on the overall slide response curve, as well as (ii) color
scale mapping of residuals R2 for each spot intensity. In
addition to visual inspection of slides, e.g., evenness of stain-
ing, sufficient levels of signal, and titration of diluted spots,
quantification data were included in determination of good
quality slides. Quantification criteria for good quality slides
included supercurve trimmed mean R2 values of 0.5 and a
residuals R2 map of at least 50% of spots in the acceptable
(green) range.
2.7 CA19-9 ELISA
CA19-9 was analyzed in 44 serum samples, for which we had
sufficient amounts, by ELISA (Tosoh, South San Francisco,
CA). This analysis was done in the Department of Laboratory
Medicine at The University of Texas M. D. Anderson Cancer
Center according to the manufacturer’s protocol.
2.8 Statistics
The nonparametric Mann–Whitney test was used to deter-
mine significance of difference in CA19-9 or albumin levels
between pancreatic cancer and noncancer samples. Correla-
tion analysis was performed by Spearman correlation and
ranked by CA19-9 levels (lowest to highest). All statistical
tests and generation of receiver operating characteristic
(ROC) curves were done with GraphPad Prism Version 4.02
(GraphPad, San Diego, CA).
3 Results
3.1 Determination of CA19-9 levels by RPPA in serum
and plasma samples
Serum or plasma samples of 71 pancreatic cancer and 30
chronic pancreatitis patients as well as 48 healthy controls
were prepared at an initial 1:10 dilution, serially diluted into
six two-fold dilutions, and stained for CA19-9. A representa-
tive RPPA slide stained with CA19-9 is shown in Fig. 1a.
Analysis of the CA19-9 levels in the slide as determined by
the supercurve program showed good curve fit of the sam-
ples, with an average trimmed mean R2 value of 0.78 for five
slides. A representative CA19-9 supercurve analysis and
residuals R2 map to demonstrate results of a successfully
stained slide is shown in Fig. 2.
Figure 1. RPPA slides stained with CA19-9 (a) and albumin (b).
Serum or plasma samples were initially diluted 1:10 then serially
diluted two-fold for a total of six dilutions. The 466 grid config-
uration programmed for arraying placed each sample and its
dilutions in rows in each grid. The 192 sample positions on the
slide include 149 unique serum and plasma samples, 30 dupli-
cates, and 6 pancreatic cell lines. The remainder contains nega-
tive control samples consisting of lysis buffer only. (a) CA19-9
slide demonstrating sample dilution and range of signal levels
between samples. Areas 1, 2, and 3 show magnified images of
representative samples on corresponding locations on the slide.
(b) Albumin slide demonstrating dilution and similar range of
signal levels between samples. The albumin slide was printed
from the same master plate as the CA19-9 slide; samples for both
slides are in identical locations.
To determine the intraslide variability, we analyzed the 30
duplicates on our array slide by comparing the original and
duplicate samples on a scatter plot (Fig. 3). This revealed a
correlation of r = 0.83 (95% CI 0.66–0.92, p,0.001), indicat-
ing the high intraslide reproducibility of the analysis. To test
the interslide variability, we compared two slides printed on
different days but stained simultaneously (Fig. 4a), as well
two slides from the same printing day that were stained
separately (Fig. 4b). The interslide correlation was likewise
found to be highly significant in both cases for different
printing (r = 0.88, 95% CI 0.84–0.91, p,0.0001) and differ-
ent staining (r = 0.93, 95% CI 0.90–0.95, p,0.001). Strik-
ingly, the intraslide, interday, and interslide correlations were
not significantly different with overlap of the confidence
intervals.
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Figure 2. Supercurve graph (top) and residuals R2 map (bottom)
of a representative slide stained for CA19-9. (Top) Supercurve
graph shows the antibody response curve produced upon utiliz-
ing mean net intensities of all spots on the slide. The slide re-
sponse curve and each sample concentration are initially esti-
mated and an improved response curve is fit for the slide based
on these sample concentrations; hence the x-axis (representing
concentration) contains no units. The estimations for slide re-
sponse curve and sample concentrations are continually iterated
until there is convergence. Upper and lower lines represent cutoff
levels for upper and lower limits of signal (reflected as minimum/
maximum valid concentration); trimmed mean R2 represents
goodness of spot fit on supercurve at the point beyond the indi-
cated concentration (25). (Bottom) Residuals R2 map represents
goodness of fit of individual spots on respective positions on the
slide to supercurve; green represents best fit; yellow, red, and
colorless (blank) progressively worse fit. Large blank areas
represent portions of the slide containing negative control sam-
ples that were excluded from supercurve analysis.
Figure 3. Comparison of CA19-9 intensities between two differ-
ent positions on the same RPPA slide. The intraslide reproduci-
bility was analyzed using Spearman correlation and ranking
CA19-9 levels from lowest to highest. Thirty sample pairs repre-
senting six samples from each group (cancer, pancreatitis, and
normal serum and plasma) were printed as duplicates in different
areas of the slide and were included in this analysis. The intra-
slide correlation was r = 0.83 (95% CI 0.66–0.92, p,0.001), indi-
cating high reproducibility.
Figure 4. Comparison of CA19-9 intensities between different
RPPA slides. (a) The interslide reproducibility due to the printing
process was determined by comparing CA19-9 levels for samples
from two slides printed on different days, and using Spearman
correlation and ranking CA19-9 levels from lowest to highest. A
significant interslide correlation between samples was observed
with r = 0.88, p,0.0001, 95% CI 0.84–0.91. (b) The interslide re-
producibility due to the staining process was determined by
comparing two slides printed together but stained on different
days, and using Spearman correlation. A significant interslide
correlation between samples was observed for different staining
days with r = 0.93, p,0.001, 95% CI 0.90–0.95.
To further validate the RPPA approach, RPPA samples
were separated according to source type (plasma or serum),
as well as diagnosis. Mean CA19-9 levels increased progres-
sively from normal to pancreatitis to pancreatic cancer in
serum samples (Fig. 5a); pancreatic cancer CA19-9 levels in
serum and plasma samples were significantly greater when
compared to normal serum or plasma. CA19-9 levels were
also significantly greater between cancer and pancreatitis
serum samples.
3.2 Loading adjustments for RPPA samples
To address potential differences between samples due to
loading differences in the RPPA samples, slides were stained
with various antibodies for identification of one or more
candidate loading control proteins. Proteins stained included
IgM and albumin. The IgM supercurve yielded less than
optimal curve fitting (trimmed mean R2 ,0.5; not shown),
which was indicative of poor staining results, and was not
used for analysis. On the other hand, slides stained with
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Figure 5. CA19-9 and albumin levels determined from RPPA
samples by supercurve and represented as log2 mean net inten-
sities and compared between pancreatic cancer, pancreatitis, and
normal serum and plasma samples. (a) Individual and mean
CA19-9 intensities in blood samples. Mean CA19-9 values show
significant differences between cancer and normal (*), as well as
cancer and pancreatitis samples (#) as analyzed by Mann–Whit-
ney two-tailed test, p,0.0001. (b) Individual and mean albumin
levels of blood sample groups. No significant difference in albu-
min levels was detected between sample groups as analyzed by
the Mann–Whitney two-tailed test.
albumin showed good titration (Fig. 1b) and yielded good
supercurve fitting (average trimmed mean R2 of four
slides = 0.81). No significant differences in albumin levels
were observed between each sample type (Fig. 5b). Based on
these criteria (in addition to our standard criteria for deter-
mining good slides), albumin was deemed an acceptable
protein to use for sample loading adjustments, and was used
in subsequent quantification analyses of CA19-9 levels in
RPPA samples.
3.3 Comparison of CA19-9 levels of pancreatic
samples: RPPA versus ELISA
The utility of the RPPA approach was next evaluated by di-
rectly comparing RPPA and clinical immunoassay of CA19-9
data. Scatter plots of CA19-9 levels of the same patient sam-
Figure 6. Correlation of CA19-9 levels of samples assayed by
both ELISA and RPPA. CA19-9 levels for ELISA were converted to
log2 values and matched samples were plotted against RPPA
samples. (a) Scatter plot comparing CA19-9 levels from ELISA
with non-normalized RPPA values, r = 0.87. (b) Scatter plot com-
paring ELISA with RPPA CA19-9 values after normalizing with
albumin for sample loading differences, r = 0.89.
ples were compared either directly or after normalization to
albumin values. Non-normalized RPPA CA19-9 levels
showed high correlation with ELISA values (r = 0.87; Fig. 6a)
while normalizing RPPA CA19-9 values with albumin
slightly increased its correlation with ELISA (r = 0.89;
Fig. 6b).
Based on these findings, we also generated ROC curves
for the serum samples comparing cancer and noncancer
(chronic pancreatitis and normal) samples. The AUC of
CA19-9 for non-normalized RPPA samples was 0.80.
Adjusting for loading differences by albumin normal-
ization for RPPA samples yielded improved results with an
AUC of 0.87 (Fig. 7a). This AUC was comparable to that of
ELISA (0.86, Fig. 7b). When the ROC curve cutoff for
RPPA was set at the mean value for CA19-9 levels in the
normal serum group (log2(x) = 27.6) and the standard
clinical cutoff used for ELISA (37 U), the specificity for
both albumin-normalized RPPA and ELISA was 71%.
Notably, the sensitivity of albumin-normalized RPPA was
greater than that of ELISA at these CA19-9 cutoff levels
(90% vs. 75%). For plasma samples, the ROC analysis,
upon normalization by albumin (Fig. 7c), gave a similar
AUC (0.87) to normalized serum. These data indicate that
the RPPA analysis works equally well with serum and
plasma samples.
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Figure 7. ROC curves of CA19-9 levels determined from RPPA
and ELISA assays. (a) ROC curves for CA19-9 levels determined
from RPPA serum samples. Open squares show albumin nor-
malized and closed squares non-normalized CA19-9 data. The
AUCs are 0.87 6 0.05 and 0.80 6 0.06, respectively; p ,0.0001. A
cutoff value oflog2(x) = 27.6 results in a sensitivity of 90% and a
specificity of 71% for the normalized RPPA data. (b) ROC curve for
the CA19-9 ELISA. The AUC is 0.86 6 0.06, p ,0.0001. With a cut-
off value of 37 U/mL, the sensitivity is 75% and the specificity
71%. (c) ROC curves for the plasma RPPA results. Open squares
show albumin normalized and closed squares non-normalized
CA19-9 data. The AUCs are 0.87 6 0.05 and 0.81 6 0.05, respec-
tively; p,0.0001. A cutoff value of log2(x) = 27.6 results in a
sensitivity of 90% and a specificity of 71% for the normalized
RPPA data.
4 Discussion
In this study, we showed that the RPPA technique, combined
with interpolation of values from supercurve, could be
applied to patient serum and plasma samples to accurately
determine CA19-9 levels. Based on ROC analyses, CA19-9 as
determined by RPPA was comparable to that of the clinical
standard ELISA. Moreover, RPPA samples adjusted for
potential loading differences showed greater sensitivity than
ELISA upon comparing cancer with noncancer samples.
These results suggest that RPPA can be used successfully as
a tool for rapidly validating blood biomarkers.
As RPPA is a relatively recently established technique,
many questions regarding validity and standardization need
to be addressed. The method itself showed robust and re-
producible intra- and interslide reproducibility. The slightly
lower intraslide correlation compared to interslide correla-
tion, albeit not statistically different, is most likely due to
regional printing and staining variances as well as the initial
manual dilutions of the sample. In the future this might be
avoided by printing the samples in triplicates and randomly
on the slide as well as use of robotics for sample dilutions.
Further, we are developing approaches and algorithms to
deal with regional staining differences.
The quality of antibody used for protein detection is a
major challenge of RPPA analysis. Unlike immunoblots
where samples can be separated by relative mobility, RPPA
samples are applied as a protein mix in one small area.
Therefore, antibody validation is a critical component to
successful RPPA assays and analyses. Initial steps in anti-
body validation involved preferential selection of relatively
stable antibodies (e.g., commercial sources, monoclonals)
and determination of antibody quality by immunoblot anal-
ysis with a single band being required for a good quality
antibody. For other antibodies such as CA19-9 that recognize
a glycosylation pattern rather than a specific protein, other
types of assays (e.g., ELISA) along with comparisons between
samples run on the two platforms might be a more feasible
means of validation for RPPA. The use of only a single anti-
body may decrease specificity. Standard ELISAs use two
antibodies, which increases the specificity of the assay. Thus,
good concordance of samples using a more stringent assay
such as ELISA to compare with RPPA appears to be a viable
procedure for RPPA antibody validation.
Another question regarding RPPA standardization
involves method of detection. We have used the colorimetric
substrate DAB as a means of detection in the visible range.
Many protein microarray studies use fluorescence detection
and recent progress has been made with this technique [22,
23]. However, we tested fluorescence detection for our RPPA
technique and found a better S/N for the DAB-based ampli-
fication procedure compared to fluorescence detection (data
not shown).
A third question regarding RPPA standardization
involves the methodology of quantification. For curve fitting,
we have used methods similar to that of other assays that rely
on a logistic curve (e.g., ELISA), with the exception that,
instead of a standard curve being established by a set of
standards, the entire slide was used to establish the “stand-
ard curve.” We feel that quantification of samples by use of
supercurve might improve accuracy as use of all spots
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(excepting outliers) can produce a well-defined logistic curve,
and it guarantees that no sample values are extrapolated.
This quantification approach could also improve the accu-
racy of ELISA analysis. However, a standard quantification
method for RPPA remains to be established.
Another important question for RPPA analysis is the
most accurate means of adjusting for loading differences
between samples. For RPPA assays involving cell lysates that
have been stained for dozens of antibodies, we have applied a
method similar to that of Nishizuka et al. [24] in which
results of all antibodies were used to determine a “correction
factor” for each sample. For serum and plasma samples, we
did not have a validated set of antibodies to work with, and so
could not normalize our sample set by our usual method.
Additionally, Hamelinck et al. [25] investigated several serum
proteins as potential normalization markers for antibody
arrays and concluded that finding a “housekeeping” protein
for serum studies is most likely unfeasible. In the current
study, we examined the usefulness of Igs and albumin as
potential normalization markers. Based on the quality of the
RPPA staining results and similar levels between cancer and
benign samples, albumin appeared to be a suitable protein
for normalization. Adjusting CA19-9 results by albumin
produced either similar (e.g., correlation between RPPA and
ELISA) or markedly improved (e.g., CA19-9 sensitivity, 90%
vs. 73%) results when compared to non-normalized samples.
The ability to adjust for loading differences is another feature
of RPPA that should enable increased accuracy of biomarker
validation.
Despite these concerns, we propose that RPPA is an ideal
assay for biomarker validation. RPPA is a high-throughput
method that requires very little sample (5 nL per sample per
slide) compared with the typical 50 mL per test required for
one standard ELISA. This tremendous savings in precious
samples not only means that testing is not limited by the
sometimes small amounts of material that are obtained, but
also that many more candidate biomarkers can be evaluated
with the same samples. This has particularly important ben-
efits in the case of some types of cancer for which sample
quantities are very limited or the rarity of the disease limits
the broad availability of the material for study. The particular
problem with pancreatic cancer is to assemble a compre-
hensive collection of serum and plasma samples, including
the important chronic pancreatitis controls. A further ad-
vantage of the RPPA assay is that the levels of several mole-
cules can be tested and compared using an identical set of
patient samples, which allows for direct statistical compar-
isons between candidate biomarkers and facilitates analyses
of biomarkers in combination. Further, many slides can be
printed at the same time and stored until needed, saving the
potential challenges to the sample of repeated freeze thawing
or the need to prepare many small aliquots of material.
Another major advantage of RPPA is cost savings. In the
study reported here, the cost per sample (excluding labor)
was $3.25 for the commercially available ELISA and $0.90
for RPPA. The RPPA cost per sample could be reduced at
least 4.6-fold using newer, higher density array machines by
which more samples per slide can be printed. In addition,
only one commercially available antibody is available for
many molecules, precluding development of a sandwich
ELISA or Luminex assay. Thus, the RPPA approach makes it
possible to analyze a large number of candidate biomarkers
for which only a single antibody is available.
RP arrays that make use of serum samples have pre-
viously been described. For example, Janzi et al. [26] used the
RPPA technique for the analysis of serum samples and
reported a highly reliable detection of IgA levels. However, in
that study, samples were arrayed at a single dilution, which
does not allow for the use of powerful statistical tools. One of
the advantages of our approach is that samples are printed in
serial dilutions. This also makes it possible to detect a wide
range of levels of potential markers/proteins. Of course,
printing serial dilutions uses more space, such that the
number of samples per slide has to be reduced. However,
with the evolution of new printing methods with more than
6000 spots per slide, this will become less of an issue.
Forward-phase, or antibody arrays have previously been
developed for biomarker studies. In antibody arrays, many
different capture antibodies are placed on the substrate,
and one sample, overlaid on the capture antibodies, is
detected either by direct or indirect labeling, such as by
detection antibodies. Orchekowski et al. [27] used an anti-
body microarray to study the serum proteins associated
with pancreatic cancer. Their array consisted of 92 anti-
bodies mostly related to inflammatory proteins and they
showed that antibodies against CA15-3 and protein-
induced vitamin K antagonist-II were able to discriminate
between cancer and benign samples. Liew et al. [28] vali-
dated a multiplex ELISA, which is similar to an antibody
microarray, except that the antibodies are printed in a 96-
well format. These forward phase arrays will likely be of
great value once a panel of useful biomarkers has been
developed, as they allow for the rapid analysis of multiple
molecules in a single sample. Regardless, our approach
analyzes many samples for a single molecule, which
enables a higher throughput that is particularly important
when evaluating candidate biomarkers.
Patwa et al. [29] developed a type of RPPA focused on
glycoproteins in complex samples, including pancreatic can-
cer, pancreatitis, and normal control serum samples. This
technique required sophisticated sample preparation,
including lectin affinity purification and RP chromatography
separation, and in some cases, the removal of highly abun-
dant proteins before array printing [30]. While this technique
enabled observation of distinct patterns that distinguished
between normal, chronic pancreatitis, and pancreatic cancer
samples, prepurification of samples has the potential to
change sample composition, which would risk loss of some
biomarkers, as was evident in our earlier studies with serum
and plasma upon albumin depletion (data not shown). In
contrast to this technique, our approach only dilutes the
samples without potentially changing the sample composi-
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tion. Furthermore, the RPPA technique used here has a
broader applicability in proteomic screening, as it is not
restricted to any particular PTM.
In summary, we have demonstrated that the RPPA tech-
nique produces results for serum and plasma samples that
are comparable to that of ELISA, and facilitates the screening
and validation of candidate biomarkers. The savings in sam-
ple volume and cost afforded by this approach should make it
possible to achieve the ultimate goal of developing better
markers for diagnosis, prognosis, and treatment outcome
prediction in cancer.
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